MONAT Hair Care Products
The MONAT litigation consolidates claims that hair-care products sold through a multi-level-marketing structure caused hair loss and scalp injury, paired with sales-practices allegations about how the products and the underlying business opportunity were marketed to independent brand partners and customers. That dual claim structure — products liability plus marketing and sales-practices theories — is itself a structural feature worth understanding: the litigation's resolution path can depend as much on how the marketing claims are proven as on the underlying product-injury theory.
With only thirteen actions centralized, this is one of the smaller active federal MDLs, which reflects a narrower and more individualized claim population than a widely used drug or device generates. General causation here is a real and non-trivial question — establishing that a specific hair-care formulation, as opposed to individual variation in hair and scalp health, causes the alleged injuries requires a dermatological and toxicological record that is less institutionally developed than in a mature drug or device MDL. That undeveloped general-causation record is likely the single largest driver of this docket's resolution risk and timeline.
Because the docket is small, there is limited bellwether-style case development to draw structural signal from, which means resolution paths here are less predictable from docket-wide patterns than in a larger, more mature MDL. Cases not resolved centrally will, per ordinary MDL procedure, be remanded to their originating courts for individual trial once coordinated pretrial proceedings conclude.
Criterica Intelligence's regulated outcomes intelligence approach applies the same structural discipline to a docket this size as to the largest MDLs in the federal system — tracking claim theory, causation posture, and resolution pathway without assigning a numeric win rate or predicting a dollar outcome for any claim. That dynamic is worth understanding on its own terms rather than assuming it will mirror the more predictable resolution arcs seen in larger, more heavily litigated drug and device MDLs.
It combines products-liability claims — that certain hair-care products caused hair loss and scalp injury — with sales-practices allegations about how the products and the associated business opportunity were marketed. The claims were centralized before Judge Darrin P. Gayles in the Southern District of Florida.
The underlying claim population is smaller: this is a single consumer-product line with individualized cosmetic-injury allegations, rather than a drug or device used by hundreds of thousands of patients, which naturally produces a smaller centralized docket.
General causation — whether the products can be shown, as a class of ingredients or formulation, to cause the alleged injuries — combined with individualized proof of use, exposure, and injury severity for each claimant.
As with other MDLs, a case not resolved centrally is generally remanded to its originating court for individual trial once coordinated pretrial proceedings conclude, following the same procedural mechanic used across the federal MDL system.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.